左甲状腺素治疗甲状腺过氧化物酶抗体阳性且甲状腺功能正常的复发性流产女性(T4LIFE试验):一项多中心、随机、双盲、安慰剂对照、3期试验
T4LIFE试验为国际多中心双盲安慰剂对照3期研究,纳入187例TPO-Ab阳性、有两次以上流产且TSH在机构参考范围内的女性,随机接受左甲状腺素或安慰剂。左甲状腺素组47例(50%)与安慰剂组45例(48%)活产,风险比1.03(95%CI 0.77-1.38),绝对风险差1.6%(95%CI -12.7-15.9)。作者不推荐对此类患者常规使用左甲状腺素。
要点
- 在TPO-Ab阳性、甲状腺功能正常且有复发性流产的女性中,左甲状腺素未提高活产率(风险比1.03,95%CI 0.77-1.38)。
- 左甲状腺素组活产47例(50%),安慰剂组45例(48%),绝对风险差1.6%(95%CI -12.7-15.9)。
- 作者不推荐对TPO-Ab阳性、有复发性流产且甲状腺功能正常的女性常规使用左甲状腺素。
核心结论
- 与安慰剂相比,左甲状腺素治疗未使TPO-Ab阳性、甲状腺功能正常且有复发性流产的女性获得更高的活产率。
- 基于本研究结果,作者不推荐对TPO-Ab阳性、有复发性流产且甲状腺功能正常的女性常规使用左甲状腺素。
研究设计与样本
- T4LIFE试验为国际、双盲、安慰剂对照、3期研究,在荷兰13家二级和三级医院、比利时1家三级医院及丹麦1家三级医院开展。
- 纳入18-42岁、TPO-Ab阳性、有两次或以上妊娠丢失且TSH浓度在机构参考范围内的女性。
- 排除抗磷脂综合征、其他自身免疫疾病、甲状腺疾病、既往参加本试验或左甲状腺素使用禁忌者。
- 孕前按1:1随机分配至口服左甲状腺素或安慰剂每日一次,左甲状腺素日剂量基于孕前TSH浓度为0.5-1.0 μg/kg体重,持续至妊娠结束。
- 主要结局为活产(妊娠24周后活产),在意向性治疗人群中分析。
主要发现
- 2013年1月1日至2019年9月19日共纳入187例女性,左甲状腺素组94例(50%),安慰剂组93例(50%)。
- 因招募缓慢,试验在纳入187例(78%)预设240例患者时提前终止。
- 左甲状腺素组47例(50%)与安慰剂组45例(48%)活产,风险比1.03(95%CI 0.77-1.38),绝对风险差1.6%(95%CI -12.7-15.9)。
- 左甲状腺素组7例(7%)与安慰剂组7例(8%)报告不良事件,均与研究操作无直接关系。
关键数值与推荐
- 主要结局活产:左甲状腺素组47例(50%)vs 安慰剂组45例(48%),风险比1.03(95%CI 0.77-1.38)。
- 绝对风险差1.6%(95%CI -12.7-15.9)。
- 不良事件:左甲状腺素组7例(7%)vs 安慰剂组7例(8%)。
临床怎么用
- 作者不推荐对TPO-Ab阳性、有复发性流产且甲状腺功能正常的女性常规使用左甲状腺素。
局限性
- 因招募缓慢,试验在纳入187例(78%)预设240例患者时提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women positive for thyroid peroxidase antibodies (TPO-Ab) have a higher risk of recurrent pregnancy loss. Evidence on whether levothyroxine treatment improves pregnancy outcomes in women who are TPO-Ab positive women with recurrent pregnancy loss is scarce. The aim of this study was to determine if levothyroxine increases live birth rates in women who were TPO-Ab positive with recurrent pregnancy loss and normal thyroid function. METHODS: The T4LIFE trial was an international, double-blind, placebo-controlled, phase 3 study done in 13 secondary and tertiary hospitals in the Netherlands, one tertiary hospital in Belgium, and one tertiary hospital in Denmark. Women (18-42 years) who were TPO-Ab positive, had two or more pregnancy losses, and had a thyroid stimulating hormone (TSH) concentration within the institutional reference range were eligible for inclusion. Women were excluded if they had antiphospholipid syndrome (lupus anticoagulant, anticardiolipin IgG or IgM antibodies, or β2-glycoprotein-I IgG or IgM antibodies), other autoimmune diseases, thyroid disease, previous enrolment in this trial, or contraindications for levothyroxine use. Before conception, women were randomly assigned (1:1) to receive either levothyroxine or placebo orally once daily. The daily dose of levothyroxine was based on preconception TSH concentration and ranged from 0·5-1·0 μg/kg bodyweight. Levothyroxine or placebo was continued until the end of pregnancy. The primary outcome was live birth, defined as the birth of a living child beyond 24 weeks of gestation measured in the intention-to-treat population. The trial was registered within the Netherlands Trial Register, NTR3364 and with EudraCT, 2011-001820-39. RESULTS: Between Jan 1, 2013, and Sept 19, 2019, 187 women were included in the study: 94 (50%) were assigned to the levothyroxine group and 93 (50%) were assigned to the placebo group. The trial was prematurely stopped when 187 (78%) of the 240 predefined patients had been included because of slow recruitment. 47 (50%) women in the levothyroxine group and 45 (48%) women in the placebo group had live births (risk ratio 1·03 [95% CI 0·77 to 1·38]; absolute risk difference 1·6% [95% CI -12·7 to 15·9]). Seven (7%) women in the levothyroxine group and seven (8%) in the placebo group reported adverse events, none of them were directly related to the study procedure. INTERPRETATION: Compared with placebo, levothyroxine treatment did not result in higher live birth rates in euthyroid women with recurrent pregnancy loss who were positive for TPO-Ab. On the basis of our findings, we do not advise routine use of levothyroxine in women who are TPO-Ab positive with recurrent pregnancy loss and normal thyroid function. FUNDING: Dutch Organization for Health Research and Development, Fonds NutsOhra, Dutch Patient Organization of Thyroid Disorders, the Jan Dekkerstichting and Dr Ludgardine Bouwmanstichting, and a personal donation through the Dutch Patient Organization of Thyroid Disorders.
引用
- van Dijk MM, Vissenberg R, Fliers E, et al. Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 35298917. doi:10.1016/S2213-8587(22)00045-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。